Thermo Fisher Scientific (TMO) Invested Capital (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Invested Capital for 18 consecutive years, with $98.3 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Invested Capital rose 12.1% year-over-year to $98.3 billion; the trailing twelve-month figure through Jun 2026 stood at $98.3 billion (up 12.1% YoY), and the FY2025 full-year result was $96.1 billion, up 16.04% from the prior year.
• Invested Capital steadied at $98.3 billion in Q2 2026 per TMO's latest filing, from $98.0 billion in the prior quarter.
• Across five years, Invested Capital topped out at $98.3 billion in Q2 2026 and bottomed at $73.4 billion in Q3 2022.
• Historically, Invested Capital has averaged $85.8 billion across 5 years, with a median of $85.3 billion in 2023.
• The sharpest annual moves came in 2022 and 2024: Invested Capital soared 41.38% in 2022, then slipped 2.61% in 2024.
• Over 5 years, Invested Capital stood at $83.9 billion in 2022, then advanced by 1.4% to $85.1 billion in 2023, then retreated by 2.61% to $82.8 billion in 2024, then gained by 16.04% to $96.1 billion in 2025, then gained by 2.31% to $98.3 billion in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $98.3 billion, $98.0 billion, and $96.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.